ArcticZymes Technologies — Investor Presentation 2024

Nov 20, 2024

Enzymes that Unlock Your Next Discovery

SEB Healthcare Seminar

November 20, 2024 CEO Michael Akoh CFO Børge Sørvoll

Overview Overview

A Norwegian biotech with growth potential A Norwegian biotech with growth potential

A provider of novel enzymes for advanced therapies and molecular Targeting segments with considerable growth Worldclass Products

• Novel enzymes for advanced therapies and molecular diagnostics

potential

Listed on the Norwegian Stock Exchange

• World class R&D team and strong manufacturing capabilities complying to Margins above 90% across all products • Strong reputation in Molecular Tools and Bioprocessing segments.
• both ISO13485 and GMP • Net Promoter Score = 84

diagnostics

No debt – 250 NMOK in Cash reserve

2

science tools companies, CDMO, Pharma and reputation in Molecular Tools and Bioprocessing Segment & Customers

World class products and

segments

US and Europe

• Targeting segments with high growth potential

Customers are life

biotech

55 employees, Headquartered in Tromsø

International management and Board

Recuring revenue streams – sticky business Sales of 119 MNOK (2023), positive cash flow and results • Customers are life science tools companies, CDMO, Pharma and Biotech

Talent & Culture

• Management team committed to creating a culture where exceptional innovation thrives
• World class R&D team
• Strong manufacturing capabilities complying to ISO13485 and GMP
• 53 employees, HQ in Tromsø
• Direct sales force in the • Direct sales in US & Europe

Strong Financials

• Margins > 90% all products
• Recurring revenue streams sticky business
• Sales of 119 MNOK (2023)
• No debt 240 MNOK in Cash reserve
• Listed on the Norwegian Stock Exchange

B2B Value chain Biomanufacturing and Molecular Tools customers

Biomanufacturing

Molecular Tools

Best-in-class Enzymes

Custom and OEM solutions – to meet customer's needs

Biomanufacturing (Therapeutics)

Viral vector, gene therapy and protein production

Removal of nucleic acids during protein production, vaccine manufacturing and viral vector preparation.

M-SAN HQ

Molecular Workflows (Research & Molecular Diagnostics)

Strategic priorities

Building a platform for long term growth – the journey has started

Partnerships Biomanufacturing and molecular tools

Increasing Commercial Reach OEM partnerships

Expanding commercial channels:

• Selling direct as well as through partners
• Active Partner Engagement:
  • Ongoing discussions with multiple potential partners
• Supply and Rebranding:
  • ArcticZymes to provide bulk material for repackaging and rebranding under partner's label
• Term Sheet Negotiations:
  • Progressing with one partner
• Execution Timeline:
  • Term sheet expected to finalize by early Q1, contingent on successful negotiation
• Revenue Impact:
  • Anticipated contribution starting in Q2/Q3 2025

CDMO opportunities

Becoming the standard nuclease on a CDMO platform

• Trend in the CGT space a return to the CDMO model
• Trough a partnership with CDMOs we will expand our reach significantly into several projects/clients
• M-SAN and SAN has been tested in an initial study with good data outcome at CDMO
• M-SAN enhances
  • Downstream recovery
  • Reduces DNA contamination
  • Minimizes vector aggregation, leading to cleaner, higher-quality lentiviral vectors
• Goal for CDMO is to start utilizing M-SAN for new projects next year on their platform

-

-

-

The future portfolio - Diversification

9

RNA based therapeutics

Targeting a broader Advanced Therapies Market

• Enzymes are key in development, analytics and manufacturing process of mRNA
• AZT is now exploring new innovations in the field of RNA therapeutics through RCN funded collaboration project.
• First major innovation is a sequence specific RNA cleaving enzyme enabling controlled fragmentation of RNA
• First patent filed February 7, 2023 further filing ongoing to secure broader IPR and lead market
• Multiple applications are possible, currently testing use for improving analytic methods for mRNA
• In contact with numerous companies with ongoing testing at 7 sites

Due to its large size, mRNA needs to be fragmented prior to analysis e.g. using LC-MS. ET-N1 can speed up and simplify the cleaving process prior to analysis.

Thank you